Pipeline Therapeutics Completes $80 Million Series C Financing
02/11/21, 1:02 PM
Location
Money raised
$80 million
Round Type
series c
Pipeline Therapeutics, a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for neuroregeneration, today announced the closing of an $80 million Series C financing.
Company Info
Location
san diego, california, united states
Additional Info
Pipeline Therapeutics is a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for neuroregeneration, including synaptogenesis, remyelination and axonal repair. The company's lead clinical program, PIPE-505, is currently enrolling patients in a phase 1/2a study to treat sensorineural hearing loss (SNHL) associated with speech-in-noise disability. The company has also initiated a Phase 1 healthy volunteer study for its second clinical program, PIPE-307, targeting multiple sclerosis. In addition, Pipeline has a portfolio of further programs addressing a range of neurological disorders and conditions. For more information, please visit www.pipelinetherapeutics.com.